Nasdaq · CIK 0001492298
SBRA Sabra Health Care REIT, Inc.
Insider trading from SEC Form 4. Last filing Mar 4, 2025.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
11
with a Form 4 at this company
Signals
Open-market buys and sells at Sabra Health Care REIT, Inc., scored.
| Score | Side | Insider | Value | Shares | Holdings change | Price context | Filed |
|---|---|---|---|---|---|---|---|
| 21Weak | buy | Cusack Catherine director | $40k | 2,500 | +4% | - |
Transactions
The last 22 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 28, 2025 | Costa Michael Lourenco Executive VP, CFO & Secretary | AGrant or award Common Stock | +3,858 | $0.00 | $0 | 344,613 | Mar 4, 2025 |
| Feb 28, 2025 | Cusack Catherine director | AGrant or award Common Stock | +833 | $0.00 | $0 | 61,416 | Mar 4, 2025 |
| Feb 28, 2025 | Barbarosh Craig A. director | AGrant or award Common Stock | +946 | $0.00 | $0 | 53,283 | Mar 4, 2025 |
| Feb 21, 2025 | Cusack Catherine director | POpen-market purchase Common Stock | +1,000 | $16.44 | $16k | 59,083 | Feb 25, 2025 |
| Feb 24, 2025 | Cusack Catherine director | POpen-market purchase Common Stock | +1,500 | $15.92 | $24k | 60,583 | Feb 25, 2025 |
| Jan 15, 2025 | Costa Michael Lourenco Executive VP, CFO & Secretary | AGrant or award Common Stock | +63,782 | $0.00 | $0 | 340,755 | Jan 17, 2025 |
| Jan 8, 2025 | Costa Michael Lourenco Executive VP, CFO & Secretary | FTax withholding Common Stock | -15,783 | $17.18 | $271k | 276,973 | Jan 10, 2025 |
| Dec 27, 2024 | Costa Michael Lourenco Executive VP, CFO & Secretary | AGrant or award Common Stock | +37,477 | $0.00 | $0 | 292,756 | Dec 31, 2024 |
| Dec 27, 2024 | FLORES JESSICA Executive VP & CAO | AGrant or award Common Stock | +8,813 | $0.00 | $0 | 69,111 | Dec 31, 2024 |
| Dec 27, 2024 | MATROS RICHARD K Chair, CEO and President | AGrant or award Common Stock | +104,716 | $0.00 | $0 | 818,739 | Dec 31, 2024 |
| Dec 27, 2024 | Nevo-Hacohen Talya Executive VP, CIO & Treasurer | AGrant or award Common Stock | +37,477 | $0.00 | $0 | 271,490 | Dec 31, 2024 |
| Nov 29, 2024 | Porter Clifton J II director | AGrant or award Common Stock | +748 | $0.00 | $0 | 47,866 | Dec 3, 2024 |
| Nov 29, 2024 | Nevo-Hacohen Talya Executive VP, CIO & Treasurer | AGrant or award Common Stock | +3,691 | $0.00 | $0 | 234,013 | Dec 3, 2024 |
| Nov 29, 2024 | Malehorn Jeffrey A. director | AGrant or award Common Stock | +826 | $0.00 | $0 | 94,779 | Dec 3, 2024 |
| Nov 29, 2024 | MATROS RICHARD K Chair, CEO and President | AGrant or award Common Stock | +11,255 | $0.00 | $0 | 714,023 | Dec 3, 2024 |
| Nov 29, 2024 | Kono Ann director | AGrant or award Common Stock | +737 | $0.00 | $0 | 46,673 | Dec 3, 2024 |
| Nov 29, 2024 | KATZMANN LYNNE S director | AGrant or award Common Stock | +826 | $0.00 | $0 | 64,554 | Dec 3, 2024 |
| Nov 29, 2024 | FOSTER MICHAEL J director | AGrant or award Common Stock | +826 | $0.00 | $0 | 74,779 | Dec 3, 2024 |
| Nov 29, 2024 | FLORES JESSICA Executive VP & CAO | AGrant or award Common Stock | +321 | $0.00 | $0 | 60,298 | Dec 3, 2024 |
| Nov 29, 2024 | Cusack Catherine director | AGrant or award Common Stock | +727 | $0.00 | $0 | 58,083 | Dec 3, 2024 |
| Nov 29, 2024 | Costa Michael Lourenco Executive VP, CFO & Secretary | AGrant or award Common Stock | +2,429 | $0.00 | $0 | 255,279 | Dec 3, 2024 |
| Nov 29, 2024 | Barbarosh Craig A. director | AGrant or award Common Stock | +826 | $0.00 | $0 | 53,508 | Dec 3, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Barbarosh Craig A.director
- Costa Michael LourencoExecutive VP, CFO & Secretary
- Cusack Catherinedirector
- FLORES JESSICAExecutive VP & CAO
- FOSTER MICHAEL Jdirector
- KATZMANN LYNNE Sdirector
- Kono Anndirector
- MATROS RICHARD KChair, CEO and President
- Malehorn Jeffrey A.director
- Nevo-Hacohen TalyaExecutive VP, CIO & Treasurer
- Porter Clifton J IIdirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.